The principal objective of the Biostatistics Core Facility is to provide statistical collaborative support of the highest quality to members of the Moffitt Cancer Center &Research Institute. Collaborative services include: assistance with design of studies, analytical aspects of grant applications, protocol development, sample size determination, and quantitative analysis and interpretation of data, usually resulting in peer-reviewed research articles. Core faculty are also involved in statistical methods development motivated by these research collaborations. The Facility, led by Dr. Michael Schell, has essentially tripled in size since the last review and now includes seven full-time faculty, five staff statisticians, and three part-time core members. The large growth in the size of Biostatistics since the last review translates to a corresponding breadth and depth of expertise. Substantial gains have occurred in the analysis of gene and tissue microarrays, proteomics, SNPs, group randomized trials, biomarkers, imaging studies, and structural equations modeling. Additional areas of strength include: clinical trials, gene microarray expression, SNP analysis, biomarker analysis, HPV incidence assessment and prevention, smoking cessation, and psychosocial issues in cancer. Recent methodological advances include development of the reduced piecewise exponential model for modeling survival, and a coordinated processing plan for the analysis of candidate biomarkers. Since the Moffitt Cancer Center is one of the leading centers for patient accruals among NCI-designated cancer centers, the Core is involved in a considerable volume of protocol activity. Faculty statisticians are members of two Scientific Review Committees, both of which meet monthly, and the Protocol Monitoring Committee. The Core requests CCSG Support of $428,029, which is 25% of its operational budget. The core continues to cost-effectively support all of the research programs.
; The Biostatistics Core is critical for the analytical quality of many research efforts at Moffitt. All institutional clinical trials are required to have statisticians, who are typically co-authors of phase II and III studies. Additionally, many studies involve high-dimensional data like gene microarrays, proteomics, SNP studies, and tissue microarrays that involve BCF members.
|Chung, Brile; Stuge, Tor B; Murad, John P et al. (2014) Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis. Cell Rep 8:871-82|
|Charbonneau, Bridget; Block, Matthew S; Bamlet, William R et al. (2014) Risk of ovarian cancer and the NF-*B pathway: genetic association with IL1A and TNFSF10. Cancer Res 74:852-61|
|Unrod, Marina; Simmons, Vani N; Sutton, Steven K et al. (2014) A randomized clinical trial of self-help intervention for smoking cessation: research design, interventions, and baseline data. Contemp Clin Trials 38:284-90|
|Osorio, Ana; Milne, Roger L; Kuchenbaecker, Karoline et al. (2014) DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS Genet 10:e1004256|
|Padron, Eric; Yoder, Sean; Kunigal, Sateesh et al. (2014) ETV6 and signaling gene mutations are associated with secondary transformation of myelodysplastic syndromes to chronic myelomonocytic leukemia. Blood 123:3675-7|
|Hampras, Shalaka S; Viscidi, Raphael P; Helzlsouer, Kathy J et al. (2014) Prospective study of seroreactivity to JC virus T-antigen and risk of colorectal cancers and adenomas. Cancer Epidemiol Biomarkers Prev 23:2591-6|
|Chen, Ning; Chon, Hye Sook; Xiong, Yin et al. (2014) Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel. Oncol Rep 31:376-83|
|Molife, L Rhoda; Yan, Li; Vitfell-Rasmussen, Joanna et al. (2014) Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors. J Hematol Oncol 7:1|
|Carvalho, Renato S; Fernandes, Vanessa C; Nepomuceno, Thales C et al. (2014) Characterization of LGALS3 (galectin-3) as a player in DNA damage response. Cancer Biol Ther 15:840-50|
|Rizwani, Wasia; Schaal, Courtney; Kunigal, Sateesh et al. (2014) Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells. PLoS One 9:e100888|
Showing the most recent 10 out of 108 publications